Teladoc Health (TDOC)
(Delayed Data from NYSE)
$8.75 USD
-0.43 (-4.68%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.77 +0.02 (0.23%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Income Statements
Fiscal Year end for Teladoc Health, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,602 | 2,407 | 2,033 | 1,094 | 553 |
Cost Of Goods | 760 | 744 | 650 | 391 | 184 |
Gross Profit | 1,842 | 1,663 | 1,382 | 703 | 369 |
Selling & Adminstrative & Depr. & Amort Expenses | 2,091 | 15,316 | 1,648 | 1,210 | 449 |
Income After Depreciation & Amortization | -249 | -13,653 | -266 | -506 | -80 |
Non-Operating Income | 51 | -1 | -39 | -9 | 0 |
Interest Expense | 22 | 9 | 80 | 61 | 29 |
Pretax Income | -220 | -13,663 | -385 | -576 | -109 |
Income Taxes | 1 | -4 | 44 | -91 | -11 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -220 | -13,660 | -429 | -485 | -99 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -220 | -13,660 | -429 | -485 | -99 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 106 | 24 | 15 | -383 | -10 |
Depreciation & Amortization (Cash Flow) | 355 | 13,677 | 281 | 123 | 70 |
Income After Depreciation & Amortization | -249 | -13,653 | -266 | -506 | -80 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 164.58 | 161.46 | 156.94 | 90.51 | 71.85 |
Diluted EPS Before Non-Recurring Items | -1.34 | -1.59 | -1.33 | -1.13 | -1.49 |
Diluted Net EPS (GAAP) | -1.34 | -84.60 | -2.73 | -5.36 | -1.38 |
Fiscal Year end for Teladoc Health, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 642.44 | 646.13 | 660.53 | 660.24 | 652.41 |
Cost Of Goods | 188.06 | 194.54 | 193.42 | 185.96 | 190.54 |
Gross Profit | 454.38 | 451.59 | 467.10 | 474.28 | 461.87 |
SG&A, R&D, and Dept/Amort Expenses | 1,295.54 | 538.72 | 502.19 | 539.00 | 533.52 |
Income After SG&A, R&D, and Dept/Amort Expenses | -841.16 | -87.13 | -35.09 | -64.72 | -71.65 |
Non-Operating Income | 13.01 | 13.57 | 24.16 | 10.81 | 11.35 |
Interest Expense | 5.65 | 5.65 | 14.45 | 5.65 | 5.84 |
Pretax Income | -833.79 | -79.20 | -25.38 | -59.56 | -66.13 |
Income Taxes | 3.88 | 2.69 | 3.52 | -2.48 | -0.95 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -837.67 | -81.89 | -28.89 | -57.07 | -65.18 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -837.67 | -81.89 | -28.89 | -57.07 | -65.18 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 170.23 | 167.73 | 166.06 | 165.12 | 164.17 |
Diluted EPS Before Non-Recurring Items | -0.28 | -0.49 | -0.17 | -0.35 | -0.40 |
Diluted Net EPS (GAAP) | -4.92 | -0.49 | -0.17 | -0.35 | -0.40 |